Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

BRAF Antikörper

Dieser Maus Monoklonal Antikörper detektiert spezifisch BRAF in WB und IHC. Es zeigt Reaktivität gegenüber Proben von Human.
Produktnummer ABIN7860917
639,45 €
Zzgl. Versandkosten 20,00 € und MwSt
100 μg
Lieferung nach: Deutschland
Lieferung in 6 bis 10 Werktagen

Kurzübersicht für BRAF Antikörper (ABIN7860917)

Target

Alle BRAF Antikörper anzeigen
BRAF (B-Raf proto-oncogene, serine/threonine kinase (BRAF))

Reaktivität

  • 252
  • 98
  • 77
  • 7
  • 5
  • 3
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
Human

Wirt

  • 213
  • 39
  • 2
Maus

Klonalität

  • 161
  • 93
Monoklonal

Konjugat

  • 147
  • 17
  • 11
  • 10
  • 8
  • 8
  • 6
  • 6
  • 6
  • 6
  • 6
  • 6
  • 3
  • 3
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
Dieser BRAF Antikörper ist unkonjugiert

Applikation

  • 154
  • 121
  • 112
  • 41
  • 31
  • 30
  • 28
  • 25
  • 23
  • 13
  • 13
  • 8
  • 3
  • 3
  • 1
  • 1
Western Blotting (WB), Immunohistochemistry (IHC)

Klon

BRAF-1626
  • Verwendungszweck

    BRAF Antibody

    Spezifität

    The 79oΩBRAF 79oΩgene encodes a cytoplasmic serine-threonine kinase, which initiates the activation of the mitogen-activated protein kinase (MAPK) signalling pathway. The oncogenic mutations in the kinase region of BRAF gene result in constitutive activation of the MAPK signalling pathway, leading to increased cell proliferation, resistance to apoptosis and tumor progression. The most common of all activating BRAF mutations leads to a substitution of valine (V) to glutamic acid (E) at the position 600 of the amino acid sequence. The 79oΩBRAF 79oΩV600E mutation is an important predictive and prognostic biomarker. The BRAF V600E mutation is detected in approximately 8 % of all solid tumours, including 45 % of papillary thyroid carcinomas, 40-60 % of melanomas, 5-15 % of colorectal adenocarcinomas, 35 % of serous low grade and borderline ovarian carcinomas, 1-3 % of non-small cell lung cancers, and 5-7 % of cholangiocarcinomas. 79oΩFurthermore, the BRAF V600E mutation is found in 100 % of hairy cell leukaemia, 79oΩ54 % Erdheim-Chester disease, 38 % of Langerhans cell histocytoses 79oΩand 60 % of pleomorphic xanthoastrocytomas. 79oΩ

    Aufreinigung

    200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G.

    Immunogen

    Recombinant fragment of human HMG20B protein (exact sequence is proprietary)

    Isotyp

    IgG1, kappa
  • Applikationshinweise

    Optimal working dilution should be determined by the investigator.

    Beschränkungen

    Nur für Forschungszwecke einsetzbar
  • Konzentration

    1.0 mg/mL

    Buffer

    Prepared in 10  mM PBS

    Konservierungsmittel

    Azide free

    Lagerung

    -20 °C,-80 °C

    Informationen zur Lagerung

    Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C.Antibody is stable for 24 months. Non-hazardous. No MSDS required.
  • Target

    BRAF (B-Raf proto-oncogene, serine/threonine kinase (BRAF))

    Andere Bezeichnung

    BRAF

    Hintergrund

    BRAF25, BRAF35, BRCA2-associated factor 35, High Mobility Group Protein 20B (HM20B), HMG box-containing protein 20B, HMG domain-containing protein HMGX2, HMG20B, SMARCE1-related protein, SMARCE1r, Sox-like transcriptional factor, SOXL

    A431, Jurkat and HeLa cells. Melanoma or Colon Carcinoma, Human Lung, Small Intestine, Gallbladder, Pancreas tissue

    Molekulargewicht

    35kDa (predicted)

    Gen-ID

    673, 406534

    UniProt

    Q9P0W2

    Pathways

    MAPK Signalweg, RTK Signalweg, Neurotrophin Signalübertragung, Ribonucleoprotein Complex Subunit Organization, Hepatitis C, Autophagie
Sie sind hier:
Chat with us!